We regret to inform you that the British Society for Immunology and our Tumour Immunology Group have decided to postpone this event 'Checkpoint blockade – understanding mechanisms, unlocking new approaches' which was due to take place on 19 March in Birmingham due to the ongoing situation with COVID-19.
We have emailed all delegates who have registered for this meeting – please check your inbox for further information on what to do.
This has been a hard decision for us as our events programme is at the heart of what we do and the activities that we provide for our members. However, after carefully reviewing the situation, we have decided that the most responsible option for us is to limit travel and large group gatherings.
I’m sure that you share in both our and our Tumour Immunology Group's disappointment that we are unable to go ahead with this event on the planned date. We are currently looking into alternative options with a view to running the event at a later date. We have contacted all registered delegates directly but if you have any questions in the meantime, please email email@example.com.
Thank you all for your support.
The BSI Tumour Immunology Group are excited to celebrate the relaunch of this Affinity Group with an inaugural high quality one-day meeting on Thursday 19 March 2020 at Austin Court Birmingham.
Immune checkpoint blockade has been making headlines for several years, transforming therapy for a range of previously untreatable advanced cancers. However, although some factors linked with improved responses are known, our understanding of the science underlying this approach is emphatically incomplete, and many patients do not respond to therapy, or experience serious side effects. The BSI Tumour Immunology Group have worked hard to put together a strong programme, focussing on exploring the fascinating and diverse immune axes that link with the checkpoint blockade concept.
In addition to providing a brief clinical perspective on current checkpoint blockade therapy, the range of speakers will explore the fundamental receptor-ligand systems involved in checkpoint blockade, key cellular subsets and regulatory axes, how the tumour and its microenvironment influence checkpoint blockade, followed by novel therapy developments in the checkpoint blockade area, including combination approaches and neoantigen reactive T cell therapy. The day will end with a networking session to bring together attendees from all stages of the therapeutic pathway, from basic scientists to translational clinicians and industry partners.
09:30–10:00 Welcome refreshments
10:00–10:15 Introduction Gary Middleton (University of Birmingham)
Session 1 – Molecular mechanisms of checkpoint blockade
Chairs: Seth Coffelt, University of Glasgow and Samantha Drennan, University of Birmingham
10:15–10:45 Simon Davis (University of Oxford) - Understanding immune-checkpoint antibodies better
10:45–11:15 Shoba Amarnath (University of Newcastle) - Programmed Cell Death-1 receptor mediated regulation of Innate Lymphoid cells within the tumour microenvironment
11:15–11:45 Sergio Quezada (University College London) - Targeting regulatory T cells in cancer: from mechanisms to new therapies
11:45–12:15 Poster viewing session
12:15–13:00 Lunch and poster viewing
Session 2 – Tumour genetics and microenvironment influencing checkpoint blockade
Chairs: Awen Gallimore, University of Cardiff and Sarah Edwards, University of Glasgow
13:00–13:30 Ping-Chih Ho (University of Lausanne) - What tumor-residing Tregs eat makes them strong but vulnerable
13:30–14:00 David Withers (University of Birmingham) - Temporal in vivo labelling models to determine how immune cells change once within the tumour microenvironment
14:00–14:30 Nicholas McGranahan (University College London) - Lung cancer evolution and immune escape
Session 3 – Novel therapeutics and combinations
Chairs: Benjamin Willcox, University of Birmingham and Sarah Lauder, University of Cardiff
15:00–15:30 Jane Robertson (Achilles Therapeutics) - Clonal neoantigen reactive T cell products and their investigation in clinical trials
15:30–16:00 Juliet Gray (University of Southampton) - Checkpoint blockade in paediatric cancers – how can success be achieved?
16:00–16:30 Gary Middleton (University of Birmingham) - Class II in colorectal cancer: towards the construction of an in situ cancer vaccine
16:30–16:45 Close and prize giving
16:45–18:00 Networking reception
Delegates are invited to submit abstracts for poster presentation. The abstract submission deadline is Thursday 20 February 2020. Please submit your abstract (max. 250 words) using this Google doc form.
Registration is now closed. If you wish to be added to the waiting list, please email: firstname.lastname@example.org You can join the BSI online - membership provides many benefits to help you progress your career. Undergraduate membership is free.
|BSI Member - Full & Early Careers *||£30|
|BSI Member - Postgraduate (including PhD, Masters)||£20|
|BSI Member - Concessionary **||£20|
|Full & Early Careers *||£50|
|Postgraduate (including PhD, Masters)||£35|
|Undergraduate (membership is free)||£10|
* Early careers includes scientists employed as post-doctoral researchers, for the first 5 years post graduation.
** Concessionary includes Parental leave, Career Breaks, Retired, Emeritus Retired.
Our thanks to the following sponsors for supporting this event.
If you are interested in sponsoring this event, please email Jane Sessenwein.